Michael Wahl1, Susan M Chang2, Joanna J Phillips2,3, Annette M Molinaro2,4, Joseph F Costello2, Tali Mazor2, Sanda Alexandrescu5, Janine M Lupo6, Sarah J Nelson6,7,8, Mitchel Berger2, Michael Prados2, Jennie W Taylor2,7, Nicholas Butowski2, Jennifer L Clarke2,7, Daphne Haas-Kogan9. 1. Department of Radiation Oncology, University of California San Francisco, San Francisco, California. 2. Department of Neurological Surgery, University of California San Francisco, San Francisco, California. 3. Department of Pathology, University of California San Francisco, San Francisco, California. 4. Department of Epidemiology and Biostatistics, University of California San Francisco, San Francisco, California. 5. Department of Pathology, Boston Children's Hospital, Harvard Medical School, Boston, Massachusetts. 6. Department of Radiology and Biomedical Imaging, University of California San Francisco, San Francisco, California. 7. Department of Neurology, University of California San Francisco, San Francisco, California. 8. Department of Bioengineering and Therapeutic Sciences, University of California San Francisco, San Francisco, California. 9. Department of Radiation Oncology, Dana-Farber Cancer Institute/Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts.
Abstract
BACKGROUND: Activation of the phosphatidylinositol 3-kinase (PI3K)/mammalian target of rapamycin (mTOR) pathway is common in patients with low-grade gliomas (LGGs), but agents that inhibit this pathway, including mTOR inhibitors, have not been studied in this population. METHODS: Fifty-eight patients with pathologic evidence of recurrence after they had initially been diagnosed with World Health Organization (WHO) grade II gliomas were enrolled into a prospective phase 2 clinical trial and received daily everolimus (RAD001) for 1 year or until progression. Tissue at the time of enrollment was analyzed for markers of PI3K/mTOR pathway activation. Thirty-eight patients underwent serial multiparametric magnetic resonance imaging, with the tumor volume and the perfusion metrics (the fractional blood volume [fBV] for capillary density and the transfer coefficient [Kps ] for vascular permeability) measured during treatment. The primary endpoint was progression-free survival at 6 months (PFS-6) in patients with WHO II disease at enrollment. RESULTS: For patients with WHO II gliomas at enrollment, the PFS-6 rate was 84%, and this met the primary endpoint (P < .001 for an improvement from the historical rate of 17%). Evidence of PI3K/mTOR activation by immunohistochemistry for phosphorylated ribosomal S6Ser240/244 (p-S6Ser240/244 ) was associated with worse progression-free survival (PFS; hazard ratio [HR], 3.03; P = .004) and overall survival (HR, 12.7; P = .01). Tumor perfusion decreased after 6 months (median decrease in fBV, 15%; P = .03; median decrease in Kps , 12%; P = .09), with greater decreases associated with improved PFS (HR for each 10% fBV decrease, 0.71; P = .01; HR for each 10% Kps decrease, 0.82; P = .04). CONCLUSIONS: Patients with recurrent LGGs demonstrated a high degree of disease stability during treatment with everolimus. PI3K/mTOR activation, as measured by immunohistochemistry for p-S6, was associated with a worse prognosis. Tumor vascular changes were observed that were consistent with the antiangiogenic effects of mTOR inhibitors. These results support further study of everolimus for LGGs. Cancer 2017;123:4631-4639.
BACKGROUND: Activation of the phosphatidylinositol 3-kinase (PI3K)/mammalian target of rapamycin (mTOR) pathway is common in patients with low-grade gliomas (LGGs), but agents that inhibit this pathway, including mTOR inhibitors, have not been studied in this population. METHODS: Fifty-eight patients with pathologic evidence of recurrence after they had initially been diagnosed with World Health Organization (WHO) grade II gliomas were enrolled into a prospective phase 2 clinical trial and received daily everolimus (RAD001) for 1 year or until progression. Tissue at the time of enrollment was analyzed for markers of PI3K/mTOR pathway activation. Thirty-eight patients underwent serial multiparametric magnetic resonance imaging, with the tumor volume and the perfusion metrics (the fractional blood volume [fBV] for capillary density and the transfer coefficient [Kps ] for vascular permeability) measured during treatment. The primary endpoint was progression-free survival at 6 months (PFS-6) in patients with WHO II disease at enrollment. RESULTS: For patients with WHO II gliomas at enrollment, the PFS-6 rate was 84%, and this met the primary endpoint (P < .001 for an improvement from the historical rate of 17%). Evidence of PI3K/mTOR activation by immunohistochemistry for phosphorylated ribosomal S6Ser240/244 (p-S6Ser240/244 ) was associated with worse progression-free survival (PFS; hazard ratio [HR], 3.03; P = .004) and overall survival (HR, 12.7; P = .01). Tumor perfusion decreased after 6 months (median decrease in fBV, 15%; P = .03; median decrease in Kps , 12%; P = .09), with greater decreases associated with improved PFS (HR for each 10% fBV decrease, 0.71; P = .01; HR for each 10% Kps decrease, 0.82; P = .04). CONCLUSIONS:Patients with recurrent LGGs demonstrated a high degree of disease stability during treatment with everolimus. PI3K/mTOR activation, as measured by immunohistochemistry for p-S6, was associated with a worse prognosis. Tumor vascular changes were observed that were consistent with the antiangiogenic effects of mTOR inhibitors. These results support further study of everolimus for LGGs. Cancer 2017;123:4631-4639.
Authors: José Baselga; Mario Campone; Martine Piccart; Howard A Burris; Hope S Rugo; Tarek Sahmoud; Shinzaburo Noguchi; Michael Gnant; Kathleen I Pritchard; Fabienne Lebrun; J Thaddeus Beck; Yoshinori Ito; Denise Yardley; Ines Deleu; Alejandra Perez; Thomas Bachelot; Luc Vittori; Zhiying Xu; Pabak Mukhopadhyay; David Lebwohl; Gabriel N Hortobagyi Journal: N Engl J Med Date: 2011-12-07 Impact factor: 91.245
Authors: Evanthia Galanis; Jan C Buckner; Matthew J Maurer; Jeffrey I Kreisberg; Karla Ballman; J Boni; Josep M Peralba; Robert B Jenkins; Shaker R Dakhil; Roscoe F Morton; Kurt A Jaeckle; Bernd W Scheithauer; Janet Dancey; Manuel Hidalgo; Daniel J Walsh Journal: J Clin Oncol Date: 2005-07-05 Impact factor: 44.544
Authors: Brett E Johnson; Tali Mazor; Chibo Hong; Michael Barnes; Koki Aihara; Cory Y McLean; Shaun D Fouse; Shogo Yamamoto; Hiroki Ueda; Kenji Tatsuno; Saurabh Asthana; Llewellyn E Jalbert; Sarah J Nelson; Andrew W Bollen; W Clay Gustafson; Elise Charron; William A Weiss; Ivan V Smirnov; Jun S Song; Adam B Olshen; Soonmee Cha; Yongjun Zhao; Richard A Moore; Andrew J Mungall; Steven J M Jones; Martin Hirst; Marco A Marra; Nobuhito Saito; Hiroyuki Aburatani; Akitake Mukasa; Mitchel S Berger; Susan M Chang; Barry S Taylor; Joseph F Costello Journal: Science Date: 2013-12-12 Impact factor: 47.728
Authors: David N Louis; Arie Perry; Guido Reifenberger; Andreas von Deimling; Dominique Figarella-Branger; Webster K Cavenee; Hiroko Ohgaki; Otmar D Wiestler; Paul Kleihues; David W Ellison Journal: Acta Neuropathol Date: 2016-05-09 Impact factor: 17.088
Authors: M J van den Bent; J S Wefel; D Schiff; M J B Taphoorn; K Jaeckle; L Junck; T Armstrong; A Choucair; A D Waldman; T Gorlia; M Chamberlain; B G Baumert; M A Vogelbaum; D R Macdonald; D A Reardon; P Y Wen; S M Chang; A H Jacobs Journal: Lancet Oncol Date: 2011-04-05 Impact factor: 41.316
Authors: K Hoang-Xuan; L Capelle; M Kujas; S Taillibert; H Duffau; J Lejeune; M Polivka; E Crinière; Y Marie; K Mokhtari; A F Carpentier; F Laigle; J M Simon; P Cornu; P Broët; M Sanson; J Y Delattre Journal: J Clin Oncol Date: 2004-08-01 Impact factor: 44.544
Authors: Heidi A Lane; Jeanette M Wood; Paul M J McSheehy; Peter R Allegrini; Anne Boulay; Joseph Brueggen; Amanda Littlewood-Evans; Sauveur-Michel Maira; Georg Martiny-Baron; Christian R Schnell; Patrizia Sini; Terence O'Reilly Journal: Clin Cancer Res Date: 2009-02-17 Impact factor: 12.531
Authors: Teri N Kreisl; Andrew B Lassman; Paul S Mischel; Neal Rosen; Howard I Scher; Julie Teruya-Feldstein; David Shaffer; Eric Lis; Lauren E Abrey Journal: J Neurooncol Date: 2008-11-19 Impact factor: 4.130
Authors: Antje Arnold; Ming Yuan; Antionette Price; Lauren Harris; Charles G Eberhart; Eric H Raabe Journal: Neuro Oncol Date: 2020-04-15 Impact factor: 12.300
Authors: David Schiff; Martin Van den Bent; Michael A Vogelbaum; Wolfgang Wick; C Ryan Miller; Martin Taphoorn; Whitney Pope; Paul D Brown; Michael Platten; Rakesh Jalali; Terri Armstrong; Patrick Y Wen Journal: Neuro Oncol Date: 2019-07-11 Impact factor: 12.300
Authors: Esraa Mohamed; Anupam Kumar; Yalan Zhang; Albert S Wang; Katharine Chen; Yunita Lim; Anny Shai; Jennie W Taylor; Jennifer Clarke; Stephanie Hilz; Mitchel S Berger; David A Solomon; Joseph F Costello; Annette M Molinaro; Joanna J Phillips Journal: Neuro Oncol Date: 2022-09-01 Impact factor: 13.029
Authors: Armin Mortazavi; Islam Fayed; Muzna Bachani; Tyrone Dowdy; Jahandar Jahanipour; Anas Khan; Jemima Owotade; Stuart Walbridge; Sara K Inati; Joseph Steiner; Jing Wu; Mark Gilbert; Chun Zhang Yang; Mioara Larion; Dragan Maric; Alexander Ksendzovsky; Kareem A Zaghloul Journal: Neuro Oncol Date: 2022-09-01 Impact factor: 13.029
Authors: Piotr Przanowski; Urszula Wasko; Zeming Zheng; Jun Yu; Robyn Sherman; Lihua Julie Zhu; Michael J McConnell; Jogender Tushir-Singh; Michael R Green; Sanchita Bhatnagar Journal: Proc Natl Acad Sci U S A Date: 2018-07-16 Impact factor: 11.205
Authors: Julie J Miller; Franziska Loebel; Tareq A Juratli; Shilpa S Tummala; Erik A Williams; Tracy T Batchelor; Isabel Arrillaga-Romany; Daniel P Cahill Journal: Neuro Oncol Date: 2019-05-06 Impact factor: 12.300
Authors: Gábor Petővári; Zoltán Hujber; Ildikó Krencz; Titanilla Dankó; Noémi Nagy; Fanni Tóth; Regina Raffay; Katalin Mészáros; Hajnalka Rajnai; Enikő Vetlényi; Krisztina Takács-Vellai; András Jeney; Anna Sebestyén Journal: Cancer Cell Int Date: 2018-12-19 Impact factor: 5.722